Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

August 21, 2019 updated by: Masonic Cancer Center, University of Minnesota

Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers

The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat metastatic breast, ovarian, endometrial or cervical cancer not responding to standard treatment.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

852A will be administered as a subcutaneous injection (SC) 2 times per week for 12 weeks (24 doses) with provisions for dose escalation or reduction based on tolerability.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Minnesota
      • Minneapolis, Minnesota, United States, 55455
        • Masonic Cancer Center, University of Minnesota

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adequate performance status:

    • Breast - Karnofsky score > 50;
    • Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score ≤2
  • If female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation.
  • Normal organ function within 14 days of study entry

  • Diagnosis of one of the following malignancies:

    • Metastatic breast cancer (BR)
    • Metastatic ovarian cancer (OV)
    • Metastatic endometrial cancer (EM)
    • Metastatic cervical cancer (CX)

Breast Cancer Inclusion Criteria:

  • Measurable metastatic disease (>1cm) in at least one site other than bone-only
  • Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease
  • Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive. If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen.

Ovarian Cancer Inclusion Criteria:

  • Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
  • Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma).
  • Subjects must have failed at least two previous chemotherapy regimens. Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens.

Endometrial Cancer Inclusion Criteria:

  • Measurable metastatic disease
  • Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens

Cervical Cancer Inclusion Criteria:

  • Measurable metastatic disease
  • Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens.

Exclusion Criteria:

  • Had/have the following prior/concurrent therapy:

    • Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A (topical or inhaled steroids are allowed)
    • Investigational drugs/agents within 14 days of first dose of 852A
    • Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A (nitrosoureas within 30 days of first dose)
    • Drugs known to induce QT interval prolongation and/or induce Torsades de pointes unless best available drug required to treat life-threatening conditions
    • Radiotherapy within 3 weeks of the first dose of 852A
    • Hematopoietic cell transplantation within 4 weeks of first dose of 852A
    • Evidence of active infection within 3 days of first dose of 852A
    • Active fungal infection or pulmonary infiltrates (prior treated disease stable for 2 weeks is allowable)
    • Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication
    • History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk
    • Uncontrolled intercurrent or chronic illness
    • Active autoimmune disease requiring immunosuppressive therapy within 30 days
    • Active coagulation disorder not controlled with medication
    • Pregnant or lactating
    • Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated
    • Any history of brain metastases or any other active central nervous system (CNS) disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intent-To-Treat
Patients treated with at least one dose - 852A subcutaneous injection.
Drug: 852A
0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
Other Names:
  • TLR-7
  • Toll-like receptor-7
Experimental: Evaluable Cohort
Patients who received all 24 doses of 852A per protocol.
Drug: 852A
0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
Other Names:
  • TLR-7
  • Toll-like receptor-7

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patients With Tumor Response (Response Evaluation Criteria in Solid Tumors) Who Received All 24 Doses of 852A.
Time Frame: after 12 weeks (24 doses of 852A)
Assessment of anti-tumor activity of 852A using Response Evaluation Criteria in Solid Tumors (RECIST) criteria to evaluate tumor response after 24 doses. Complete Response (CR)= disappearance of all target lesions, Partial Response (PR) = at least 30% decrease in sum of longest diameter of target lesions, Progressive Disease (PD) = at least 25% increase in sum of longest diameter of target lesions, Stable Disease = neither PR or PD.
after 12 weeks (24 doses of 852A)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Difference Values for Interleukin 1 Receptor Antagonist (IKL1ra)
Time Frame: Prior to Dose 1 and 6 hours after Dose 1
Measures the difference of IL1ra (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.
Prior to Dose 1 and 6 hours after Dose 1
Mean Difference Values for 10 kDa Interferon-gamma-induced Protein (IP-10)
Time Frame: Prior to Dose 1 and 6 Hours Post-Dose
Measures differences in IP-10 (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.
Prior to Dose 1 and 6 Hours Post-Dose
Mean Difference Values for Macrophage Inflammatory Protein-1 Alpha (MIP-1a)
Time Frame: Prior to Dose 1 and 6 Hours Post-Dose
Measures difference in MIP-1a (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.
Prior to Dose 1 and 6 Hours Post-Dose
Mean Difference Values for Macrophage Inflammatory Protein-1 Beta (MIP-1b)
Time Frame: Prior to Dose 1 and 6 Hours Post-Dose
Measures difference in Macrophage Inflammatory Protein-1 Beta (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.
Prior to Dose 1 and 6 Hours Post-Dose
Mean Difference Values for Soluble CD40 Ligand (sCD40L)
Time Frame: Prior to Dose 1 and 6 Hours Post-Dose
Measures difference in Soluble CD40 ligand (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.
Prior to Dose 1 and 6 Hours Post-Dose
Mean Difference Values for Tumor Necrosis Factor-alpha (TNF-a)
Time Frame: Prior to Dose 1 and 6 Hours Post-Dose
Measures difference in Tumor necrosis factor-alpha (cytokine) values as a means of immune activation pre-treatment and 6 hours post-treatment in patients that received at least one dose of study treatment with 852A.
Prior to Dose 1 and 6 Hours Post-Dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Masonic Cancer Center, University of Minnesota

Collaborators

Pfizer

Investigators

  • Principal Investigator: Sarah Cooley, MD, Masonic Cancer Center, University of Minnesota

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2006

Primary Completion (Actual)

December 1, 2007

Study Completion (Actual)

December 1, 2008

Study Registration Dates

First Submitted

April 27, 2006

First Submitted That Met QC Criteria

April 27, 2006

First Posted (Estimate)

April 27, 2006

Study Record Updates

Last Update Posted (Actual)

August 26, 2019

Last Update Submitted That Met QC Criteria

August 21, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 06US03IMP-852A
  • MT2006-02 (Other Identifier: Blood and Bone Marrow Transplantation Program)
  • 2006LS005 (Other Identifier: Masonic Cancer Center, University of Minnesota)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Cancer

Clinical Trials on 852A

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe